research use only
Cat.No.S8379
| Related Targets | HDAC PARP ATM/ATR WRN DNA/RNA Synthesis Topoisomerase PPAR Sirtuin Casein Kinase eIF |
|---|---|
| Other DNA-PK Inhibitors | Nedisertib (M3814) AZD7648 NU7441 (KU-57788) KU-0060648 VX-984 NU7026 CC-115 LTURM34 Compound 401 |
| Molecular Weight | 459.95 | Formula | C22H22ClN3O4S |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1943733-16-1 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | COC1=CC=C(C=C1)S(=O)(=O)NCC2=CC=C(C=C2)C(=O)NCCC3=NC=C(C=C3)Cl | ||
|
In vitro |
DMSO
: 91 mg/mL
(197.84 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Targets/IC50/Ki |
HDR
|
|---|---|
| In vitro |
YU238259 exhibits potent synthetic lethality in the setting of DNA damage response and DNA repair defects. Treatment with this compound is not only synergistic with ionizing radiation (IR), etoposide, and PARP inhibition, but this synergism is heightened by BRCA2-deficiency. Synthetic lethality of this chemical in HDR-deficient cells results from accumulation of unresolved DSBs following additional inhibition of residual HDR pathway activity. Inhibition of HDR activity by this agent has little to no effect on the NHEJ pathway. It sensitizes tumour cells to radiation therapy and DSB-inducing chemotherapy .
|
| In vivo |
Growth of BRCA2-deficient human tumour xenografts in nude mice is significantly delayed by YU238259 treatment even in the absence of concomitant DNA-damaging therapy.
|
References |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.